BOOST – Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement

Inclusion Criteria:

Patient underwent a CRT replacement within the last two weeks, triggered by either the elective replacement indicator (ERI)/end of life (EOL), or by receiving a CRT-D device as an upgrade from a CRT-P device.
Patient has received an FDA approved SJM CRT device as a replacement to the old CRT device within the last two weeks.
Patient has the ability to complete a 6-minute hall walk without any assistance.
Patient is willing to provide written informed consent.
Patient has the ability to independently comprehend and complete a QOL questionnaire.
Patient is geographically stable and is willing to comply with the required follow-up schedule.

Exclusion Criteria:

Patient had paced/sensed AV and/or V-V delay optimization using QuickOpt before CRT replacement.
Patient had any paced/sensed AV and/or V-V delay optimization within 3 months before CRT replacement.
Patient has an ability to walk ≥ 450 meters (≥ 1476 feet) in 6 minutes.
Adequate patient's echocardiography/Doppler images will not be available.
Patient is expected to receive a heart transplant during the duration of the study.
Patient has an epicardial ventricular lead system (Active or Inactive).
Patient has limited intrinsic atrial activity (≤ 40 bpm).
Patient has persistent or permanent atrial fibrillation (AF).
Patient has 2° or 3° heart block.
Patient's life expectancy is less than 1 year.
Patient is less than 18 years old.
Patient is pregnant.
Patient is on IV inotropic agents 1 month prior to CRT replacement.